Quick Answer
KIORA PHARMACEUTICALS INC reported Operating Income Loss of -$12.83 million for the year ending 2025.
- KIORA PHARMACEUTICALS INC showed a decrease of -384.5% in Operating Income Loss from 2024 to 2025.
- This data is from KIORA PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on March 25, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2016: -$3.83 million | Q3 2016: -$3.38 million | Q1 2017: -$2.92 million | Q2 2017: -$3.33 million | Q3 2017: -$4.14 million | Q1 2018: -$2.38 million | Q2 2018: -$2.80 million | Q3 2018: -$3.18 million | Q1 2019: $828.6 thousand | Q2 2019: -$1.87 million | Q3 2019: -$3.45 million | Q1 2020: -$1.97 million | Q2 2020: -$1.72 million | Q3 2020: -$2.01 million | Q1 2021: -$2.01 million | Q2 2021: -$2.82 million | Q3 2021: -$3.04 million | Q1 2022: -$3.57 million | Q2 2022: -$2.40 million | Q3 2022: -$3.70 million | Q1 2023: -$1.92 million | Q2 2023: -$2.63 million | Q3 2023: -$5.92 million | Q1 2024: $13.22 million | Q2 2024: -$2.54 million | Q3 2024: -$3.60 million | Q1 2025: -$2.33 million | Q2 2025: -$2.40 million | Q3 2025: -$794.4 thousand.
- Over the full 6 years of available data (2020 to 2025), KIORA PHARMACEUTICALS INC's Operating Income Loss has declined by 56.2%.
- Historical annual values: Fiscal year 2025: -$12.83 million | Fiscal year 2024: $4.51 million | Fiscal year 2023: -$12.59 million | Fiscal year 2022: -$12.31 million | Fiscal year 2021: -$14.24 million | Fiscal year 2020: -$8.21 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: